Randomized Study Comparing Nipocalimab and Intravenous Immunoglobulin in Pregnancies at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
50
Participants Needed
38
Research Sites
103 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT, a condition affecting unborn and newborn babies. This Phase 3 randomized study compares nipocalimab with intravenous immunoglobulin IVIG treatment in pregnant women at risk of FNAIT. The trial is led by Janssen Research & Development, LLC and focuses on improving outcomes for fetuses and neonates facing serious bleeding risks.
Pregnant participants with specific antibodies against HPA-1a andor HPA-5b are randomly assigned to receive either nipocalimab or IVIG. Nipocalimab is given intravenously starting between weeks 13 and 18 of pregnancy until delivery. IVIG is also given intravenously, starting at week 12 for high-risk pregnancies or week 20 for standard-risk pregnancies, along with oral prednisone which is tapered off after delivery based on the doctors judgment or participant tolerance.
During the study, participants undergo regular assessments including blood tests to monitor platelet counts in their newborns, evaluation of bleeding events, and tracking of any adverse effects in both the mother and child. The main outcome is the presence of death, severe bleeding, or very low platelet counts in the fetus or newborn up to one week after birth. Longer-term follow-up includes developmental assessments of the infant at one and two years. The total study duration extends up to the end of 2029 with safety monitoring through the first 24 weeks postpartum and infant follow-up for up to 104 weeks.
CONDITIONS
Brief Title
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Nipocalimab
IVIG + Prednisone
Current standard care
What it is
Intravenous nipocalimab monoclonal antibody investigated to manage pregnancies at high risk of FNAIT
Intravenous immunoglobulins plus oral prednisone given as part of the randomized comparator arm
Antenatal management using IVIG with or without corticosteroids is currently used in pregnancies at risk of FNAIT
Role in trial
Active investigational treatment arm
Active comparator investigational arm
Provides external clinical context but is not part of the trial
Primary use or goal
Aim to prevent severe fetal or neonatal bleeding and death associated with FNAIT
Also aimed at preventing severe fetal or neonatal bleeding and death in FNAIT
Used antenatally to reduce risk of intracranial hemorrhage and severe thrombocytopenia in FNAIT pregnancies
Administration
Given intravenously to the pregnant participant
IVIG given intravenously plus oral prednisone
Typically administered as weekly IVIG infusions, sometimes with corticosteroids
Evidence status
Efficacy is being evaluated in this trial; no published results yet
Also under investigation in this trial with no efficacy results yet
Clinically used based on expert recommendations, but randomized evidence is limited
Important risks
Safety profile not yet established—trial will monitor maternal and neonatal adverse events
Known risks of IVIG and corticosteroids include infusion reactions and steroid side effects, being monitored in this trial
IVIG infusions and steroids have established maternal risks such as infusion reactions and steroid-related effects
Important limitations
No efficacy or safety results published yet; unknown benefit-risk profile
Also lacks trial results; combination may have steroid‑related risks
Guideline recommendations are based on limited randomized data and consensus rather than large trials
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 45Years
FEMALE
Eligibility Criteria
You may qualify if you...
Pregnant women with an estimated gestational age between 13 and 18 weeks at the first visit
History of at least one previous pregnancy affected by FNAIT
Presence of maternal anti-HPA-1a and/or anti-HPA-5b antibodies with positive fetal HPA genotype confirmed by cell-free fetal DNA
Stable health status based on medical examination and tests
Willingness to avoid participation in other investigational therapy studies until last follow-up visit
You will not qualify if you...
Currently pregnant with multiple gestations (twins or more)
History of severe preeclampsia in a previous pregnancy
History of myocardial infarction, unstable ischemic heart disease, or stroke
Known allergy or intolerance to nipocalimab, IVIG, or prednisone
Confirmed or suspected immunodeficiency conditions or relevant family history unless ruled out
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - From gestational week 12 to delivery
Participants receive either nipocalimab or intravenous immunoglobulin (IVIG) starting between weeks 12 and 20 of pregnancy, depending on risk. Prednisone is also given with IVIG and tapered after delivery based on tolerance.
Regular visits during pregnancy until delivery
Postnatal Follow-up
Duration - Up to 104 weeks after birth
Mothers and their newborns are monitored for safety and health outcomes, including bleeding events and platelet counts up to one week after birth. Infant development is assessed up to two years.
Periodic visits and assessments after birth
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Nipocalimab Versus Placebo to Reduce Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-Risk Pregnant Women
Randomized Study Comparing Nipocalimab and Intravenous Immunoglobulin in Pregnancies at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.